Natural exposure to cutaneous anthrax gives long-lasting T cell immunity encompassing infection-specific epitopes

Journal of Immunology

Volumn 184, Issue 7, 2010, Pages 3814-3821

  Ingram, Rebecca J ^a   Metan, Gökhan ^e   Maillere, Bernard ^f   Doganay, Mehmet ^e   Ozkul, Yusuf ^e   Kim, Louise U ^a   Baillie, Les ^b   Dyson, Hugh ^c   Williamson, E Diane ^c   Chu, Karen K ^a   Ascough, Stephanie ^a   Moore, Steven ^g   Huwar, Theresa B ^h   Robinson, John H ^d   Sriskandan, Shiranee ^a   Altmann, Daniel M ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e ERCIYES UNIVERSITY   (Turkey)

^f SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^g CytomX Therapeutics Inc   (United States)

^h UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; ANTHRAX VACCINE; EPITOPE; HLA ANTIGEN; BACTERIAL ANTIGEN; BACTERIAL TOXIN;

ADAPTIVE IMMUNITY; ALLELE; ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL INFECTION; BIOLOGICAL WARFARE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENDEMIC DISEASE; HUMAN; HUMAN CELL; IMMUNOLOGICAL MEMORY; LETHAL GENE; PRIORITY JOURNAL; PROTEIN DOMAIN; TURKEY (REPUBLIC); VACCINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY;

ANTHRAX; ANTHRAX VACCINES; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; CD4-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNOLOGIC MEMORY;

EID: 77951627710     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901581     Document Type: Article

References (44)

1. Baillie, L. W. 2006. Past, imminent and future human medical countermeasures for anthrax. J. Appl. Microbiol. 101: 594-606.
2. Schmid, G., and A. Kaufmann. 2002. Anthrax in Europe: its epidemiology, clinical characteristics, and role in bioterrorism. Clin. Microbiol. Infect. 8: 479-488.
3. Atlas, R. M. 2002. Bioterrorism: from threat to reality. Annu. Rev. Microbiol. 56: 167-185.
4. Greene, C. M., J. Reefhuis, C. Tan, A. E. Fiore, S. Goldstein, M. J. Beach, S. C. Redd, D. Valiante, G. Burr, J. Buehler, et al; CDC New Jersey Anthrax Investigation Team. Centers for Desease Control and Prevention. 2002. Epidemiologic investigations of bioterrorism-related anthrax, New Jersey, 2001. Emerg. Infect. Dis. 8: 1048-1055.
5. Mock, M., and A. Fouet. 2001. Anthrax. Annu. Rev. Microbiol. 55: 647-671.
6. Collier, R. J., and J. A. Young. 2003. Anthrax toxin. Annu. Rev. Cell Dev. Biol. 19: 45-70.
7. Bradley, K. A., J. Mogridge, M. Mourez, R. J. Collier, and J. A. Young. 2001. Identification of the cellular receptor for anthrax toxin. Nature 414: 225-229.
8. Young, J. A., and R. J. Collier. 2007. Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annu. Rev. Biochem. 76: 243-265.
9. Wei, W., Q. Lu, G. J. Chaudry, S. H. Leppla, and S. N. Cohen. 2006. The LDL receptor-related protein LRP6 mediates internalization and lethality of anthrax toxin. Cell 124: 1141-1154.
10. Turnbull, P. C., S. H. Leppla, M. G. Broster, C. P. Quinn, and J. Melling. 1988. Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Med. Microbiol. Immunol. (Berl.) 177: 293-303.
11. Quinn, C. P., P. M. Dull, V. Semenova, H. Li, S. Crotty, T. H. Taylor, E. Steward-Clark, K. L. Stamey, D. S. Schmidt, K. W. Stinson, et al. 2004. Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J. Infect. Dis. 190: 1228-1236.
12. Doolan, D. L., D. A. Freilich, G. T. Brice, T. H. Burgess, M. P. Berzins, R. L. Bull, N. L. Graber, J. L. Dabbs, L. L. Shatney, D. L. Blazes, et al. 2007. The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics. J. Infect. Dis. 195: 174-184.
13. Walsh, J. J., N. Pesik, C. P. Quinn, V. Urdaneta, C. A. Dykewicz, A. E. Boyer, J. Guarner, P. Wilkins, K. J. Norville, J. R. Barr, et al. 2007. A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. Clin. Infect. Dis. 44: 968-971.
14. Reuveny, S., M. D. White, Y. Y. Adar, Y. Kafri, Z. Altboum, Y. Gozes, D. Kobiler, A. Shafferman, and B. Velan. 2001. Search for correlates of protective immunity conferred by anthrax vaccine. Infect. Immun. 69: 2888-2893.
15. Baillie, L., T. Townend, N. Walker, U. Eriksson, and D. Williamson. 2004. Characterization of the human immune response to the UK anthrax vaccine. FEMS Immunol. Med. Microbiol. 42: 267-270.
16. Williamson, E. D., I. Hodgson, N. J. Walker, A. W. Topping, M. G. Duchars, J. M. Mott, J. Estep, C. Lebutt, H. C. Flick-Smith, H. E. Jones, et al. 2005. Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax. Infect. Immun. 73: 5978-5987.
17. Turnbull, P. C., M. G. Broster, J. A. Carman, R. J. Manchee, and J. Melling. 1986. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect. Immun. 52: 356-363.
18. Chitlaru, T., O. Gat, H. Grosfeld, I. Inbar, Y. Gozlan, and A. Shafferman. 2007. Identification of in vivo-expressed immunogenic proteins by serological proteome analysis of the Bacillus anthracis secretome. Infect. Immun. 75: 2841-2852.
19. Gu, M. L., S. H. Leppla, and D. M. Klinman. 1999. Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen. Vaccine 17: 340-344.
20. Fish, D. C., B. G. Mahlandt, J. P. Dobbs, and R. E. Lincoln. 1968. Purification and properties of in vitro-produced anthrax toxin components. J. Bacteriol. 95: 907-918.
21. Gorse, G. J., W. Keitel, H. Keyserling, D. N. Taylor, M. Lock, K. Alves, J. Kenner, L. Deans, and M. Gurwith. 2006. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine 24: 5950-5959.
22. Laughlin, E. M., J. D. Miller, E. James, D. Fillos, C. C. Ibegbu, R. S. Mittler, R. Akondy, W. Kwok, R. Ahmed, and G. Nepom. 2007. Antigen-specific CD4+ T cells recognize epitopes of protective antigen following vaccination with an anthrax vaccine. Infect. Immun. 75: 1852-1860.
23. Kwok, W. W., J. Yang, E. James, J. Bui, L. Huston, A. R. Wiesen, and M. Roti. 2008. The anthrax vaccine adsorbed vaccine generates protective antigen (PA)-Specific CD4+ T cells with a phenotype distinct from that of naive PA T cells. Infect. Immun. 76: 4538-4545.
24. Doherty, P. C., and J. P. Christensen. 2000. Accessing complexity: the dynamics of virus-specific T cell responses. Annu. Rev. Immunol. 18: 561-592.
25. Agrawal, A., J. Lingappa, S. H. Leppla, S. Agrawal, A. Jabbar, C. Quinn, and B. Pulendran. 2003. Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature 424: 329-334. (Pubitemid 36899376)
26. Rosenberger, C. M., and B. B. Finlay. 2003. Phagocyte sabotage: disruption of macrophage signalling by bacterial pathogens. Nat. Rev. Mol. Cell Biol. 4: 385-396.
27. Fukao, T. 2004. Immune system paralysis by anthrax lethal toxin: the roles of innate and adaptive immunity. Lancet Infect. Dis. 4: 166-170.
28. Moayeri, M., and S. H. Leppla. 2004. The roles of anthrax toxin in pathogenesis. Curr. Opin. Microbiol. 7: 19-24.
29. Alileche, A., E. R. Serfass, S. M. Muehlbauer, S. A. Porcelli, and J. Brojatsch. 2005. Anthrax lethal toxin-mediated killing of human and murine dendritic cells impairs the adaptive immune response. PLoS Pathog. 1: e19.
30. Abrami, L., N. Reig, and F. G. van der Goot. 2005. Anthrax toxin: the long and winding road that leads to the kill. Trends Microbiol. 13: 72-78. (Pubitemid 40174866)
31. Baldari, C. T., F. Tonello, S. R. Paccani, and C. Montecucco. 2006. Anthrax toxins: a paradigm of bacterial immune suppression. Trends Immunol. 27: 434-440.
32. Reig, N., A. Jiang, R. Couture, F. S. Sutterwala, Y. Ogura, R. A. Flavell, I. Mellman, and F. G. van der Goot. 2008. Maturation modulates caspase-1-independent responses of dendritic cells to Anthrax lethal toxin. Cell. Microbiol. 10: 1190-1207.
33. Paccani, S. R., F. Tonello, R. Ghittoni, M. Natale, L. Muraro, M. M. D'Elios, W. J. Tang, C. Montecucco, and C. T. Baldari. 2005. Anthrax toxins suppress T lymphocyte activation by disrupting antigen receptor signaling. J. Exp. Med. 201: 325-331.
34. Pannifer, A. D., T. Y. Wong, R. Schwarzenbacher, M. Renatus, C. Petosa, J. Bienkowska, D. B. Lacy, R. J. Collier, S. Park, S. H. Leppla, et al. 2001. Crystal structure of the anthrax lethal factor. Nature 414: 229-233.
35. Texier, C., S. Pouvelle, M. Busson, M. Hervé, D. Charron, A. Ménez, and B. Maillère. 2000. HLA-DR restricted peptide candidates for bee venom immunotherapy. J. Immunol. 164: 3177-3184. (Pubitemid 30148979)
36. Venturi, V., D. A. Price, D. C. Douek, and M. P. Davenport. 2008. The molecular basis for public T-cell responses? Nat. Rev. Immunol. 8: 231-238.
37. Sewell, A. K., D. A. Price, H. Teisserenc, B. L. Booth, Jr., U. Gileadi, F. M. Flavin, J. Trowsdale, R. E. Phillips, and V. Cerundolo. 1999. IFN-gamma exposes a cryptic cytotoxic T lymphocyte epitope in HIV-1 reverse transcriptase. J. Immunol. 162: 7075-7079.
38. Lewinsohn, D. A., E. Winata, G. M. Swarbrick, K. E. Tanner, M. S. Cook, M. D. Null, M. E. Cansler, A. Sette, J. Sidney, and D. M. Lewinsohn. 2007. Immunodominant tuberculosis CD8 antigens preferentially restricted by HLA-B. PLoS Pathog. 3: 1240-1249.
39. Lara-Tejero, M., and E. G. Pamer. 2004. T cell responses to Listeria monocytogenes. Curr. Opin. Microbiol. 7: 45-50.
40. Sette, A., W. Fleri, B. Peters, M. Sathiamurthy, H. H. Bui, and S. Wilson. 2005. A roadmap for the immunomics of category A-C pathogens. Immunity 22: 155-161. (Pubitemid 40255707)
41. Doganay, M., and G. Metan. 2008. Human anthrax in Turkey from 1990 to 2007. Vector Borne Zoonotic Dis. 9: 131-140.
42. Shlyakhov, E., E. Rubinstein, and I. Novikov. 1997. Anthrax post-vaccinal cellmediated immunity in humans: kinetics pattern. Vaccine 15: 631-636. (Pubitemid 27240477)
43. Shlyakhov, E. N., and E. Rubinstein. 1994. Human live anthrax vaccine in the former USSR. Vaccine 12: 727-730. (Pubitemid 24182373)
44. Chou, P. J., C. A. Newton, I. Perkins, H. Friedman, and T. W. Klein. 2008. Suppression of dendritic cell activation by anthrax lethal toxin and edema toxin depends on multiple factors including cell source, stimulus used, and function tested. DNA Cell Biol. 27: 637-648.